# Omega Funds

> Omega Funds is a VC fund in Boston backing Biotechnology and Health Care. See 161 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Boston, United States
- Total investments: 161
- Last investment: May 2026
- Lead investor: 27%
- Last fund: Apr 2023
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/omegafunds/
- Website: https://omegafunds.com

Omega Funds is a venture capital firm that seeks to invest in the life sciences, digital health, immunology, rare diseases, precision medicine, oncology, cybersecurity, and SaaS sectors.

## Contacts

5 contacts available for Omega Funds. Shizune tracks 13 team members at Omega Funds. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/omega-funds?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $16M–$187M |
| Series B | $37M–$162M |
| Series C | $14M–$208M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 79 | 49% |
| Health Care | 46 | 29% |
| Therapeutics | 34 | 21% |
| Pharmaceutical | 33 | 20% |
| Medical | 32 | 20% |

41 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 39 | 24% |
| Series B | 36 | 22% |
| Series C | 17 | 11% |
| Funding Round | 15 | 9% |
| Post-IPO Equity | 9 | 6% |

10 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 73 | 45% |
| Switzerland | 8 | 5% |
| United Kingdom | 4 | 2% |
| Germany | 3 | 2% |
| Canada | 2 | 1% |

10 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Michael Powell | Executive Partner | 12 | https://shizune.co/investors/profile/michael-powell |
| Michael Powell | Executive Partner | 6 | https://shizune.co/investors/profile/mike-powell |
| Otello Stampacchia | Founder | 20 | https://shizune.co/investors/profile/otello-stampacchia |
| Vincent Ossipow | Partner | 5 | https://shizune.co/investors/profile/vincent-ossipow |
| Alexia Pearsall | Chief Financial Officer | 0 | https://shizune.co/investors/profile/alexia-pearsall-d875 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Windward Bio | Windward Bio is a clinical-stage drug development company focused on improving outcomes for individuals with advanced immunological diseases, particularly severe respiratory conditions. The company is advancing a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 development while creating innovative bispecific programsfor various immunological disorders. Led by a team of biopharmaceutical executives, Windward Bio aims to address significant unmet medical needs in this field. | $165M | Series B | May 04, 2026 |  |
| ImageneBio | It is a leading biotech company focused on immunology-related therapeutic areas. | $30M | Post-IPO Equity | Apr 13, 2026 |  |
| Third Arc Bio | Third Arc Bio is a biotech company developing multifunctional antibodies for inflammatory and immunology diseases. Its drug development engine delivers superior biologics optimized to create T-cell engagement by leveraging two technologies that power a pipeline of high-value therapeutics – a solid tumor synergy platform and an I&I platformthat offers a novel approach to precision immune regulation at a tissue-specific level to achieve superior efficacy and safety. | $52M | Series A | Feb 04, 2026 |  |
| Caldera Therapeutics | Caldera was founded in 2025 to advance innovative biologics in IBD, assembling a senior leadership team with deep experience in the discovery and development of IBD therapeutics and a proven track record of building biotechnology companies through to successful exits.Caldera Therapeutics is a biotech company engaged in the development ofbispecific antibody CLD-423 for inflammatory bowel disease (IBD). | $37.5M | Series A | Jan 14, 2026 |  |
| Alveus Therapeutics | Alveus Therapeutics is a clinical-stage biotech company developing therapies for obesity and metabolic diseases. | $197M | Series A | Jan 08, 2026 |  |
| Spiro Medical | Spiro Medical is a medical device company developing a groundbreaking Pulmonary Neuromodulation (PNM) System for asthma treatment. The company offers a drug-free approach to controlling severe, chronic airway diseases through its Spiro Neuromodulation System. | $67M | Series A | Jan 07, 2026 |  |
| Protego Biopharma | Protego Biopharma develops therapeutics based on the clear human genetic link, excellent human safety profile, proof-of-principle efficacy. The company was founded in 2011 and is headquartered in San Diego, California. | $130M | Series B | Dec 01, 2025 |  |
| Artios Pharma | Artios is an independent DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. Established in May 2016, the Company is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery. Artios is building a pipeline of next-generation DDR programs, including through a uniquepartnership with Cancer Research Technology (CRT), the development and commercialization arm of Cancer Research UK (CRUK), and with leading DNA repair researchers worldwide. The Company’s investors include SV Life Sciences, Merck Ventures, Imperial Innovations, Arix Bioscience PLC, CRT Pioneer Fund (managed by Sixth Element Capital), and AbbVie Ventures. Artios is based at the Babraham Institute in Cambridge, UK. | $115M | Series D | Nov 17, 2025 |  |
| NRG Therapeutics | NRG Therapeutics is a drug discovery company focussed on therapeutic approaches that will restore mitochondrial function and slow or halt the progression of neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease and motor neurone disease. Founded in 2018 by a team of experienced biotech and pharmaceutical industryprofessionals, with a background in neuroscience drug discovery, NRG Therapeutics will initially focus on the discovery and development of brain penetrant mitochondrial permeability transition pore inhibitors for the treatment of Parkinson’s disease. | $67.8M | Series B | Sep 08, 2025 |  |
| NRG Therapeutics | NRG Therapeutics is a drug discovery company focussed on therapeutic approaches that will restore mitochondrial function and slow or halt the progression of neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease and motor neurone disease. Founded in 2018 by a team of experienced biotech and pharmaceutical industryprofessionals, with a background in neuroscience drug discovery, NRG Therapeutics will initially focus on the discovery and development of brain penetrant mitochondrial permeability transition pore inhibitors for the treatment of Parkinson’s disease. | $67.8M | Series B | Sep 08, 2025 |  |

10 of 161 investments shown.

## Co-investors
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 32 deals together
- [Atlas Venture](https://shizune.co/investors/profile/atlas-venture) — VC Fund, 18 deals together
- [Surveyor Capital](https://shizune.co/investors/profile/surveyor-capital) — VC Fund, 18 deals together
- [Janus Henderson Investors](https://shizune.co/investors/profile/janus-henderson-investors) — VC Fund, 15 deals together
- [Casdin Capital](https://shizune.co/investors/profile/casdin-capital) — VC Fund, 14 deals together
- [Invus](https://shizune.co/investors/profile/invus) — VC Fund, 14 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Vaekstfonden](https://shizune.co/investors/profile/v%C3%A6kstfonden) — VC Fund
- [PSV](https://shizune.co/investors/profile/preseed-innovation) — VC Fund
- [Seed Capital](https://shizune.co/investors/profile/seed-capital) — VC Fund

## Featured in investor lists
- [Biotech Investors](https://shizune.co/investors/biotech-investors)
- [Biotech VC Funds](https://shizune.co/investors/biotech-vc-funds)
- [Biotechnology Investors](https://shizune.co/investors/biotechnology-investors)
- [Biotechnology VC Funds](https://shizune.co/investors/biotechnology-vc-funds)
- [Biotech Investors in United States](https://shizune.co/investors/biotech-investors-united-states)
- [Biotech VC Funds in United States](https://shizune.co/investors/biotech-vc-funds-united-states)

## FAQ

### What does Omega Funds invest in?

Omega Funds invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 161 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Omega Funds's check size?

Omega Funds typically joins rounds of $16M–$187M at Series A, $37M–$162M at Series B and $14M–$208M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Omega Funds participates in.

### How do I contact Omega Funds?

Public channels for Omega Funds include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Omega Funds?

The team at Omega Funds includes Michael Powell (Executive Partner), Michael Powell (Executive Partner) and Otello Stampacchia (Founder), among 13 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co